Moderna has reported a surprise fourth-quarter profit, attributing the success to cost-cutting measures, deferred payments, and an increase in market share for its Covid vaccine against its rival, Pfizer. The company announced adjusted earnings per share (EPS) of $0.55, surpassing analysts' expectations of a loss of $1.06, with revenue reaching $2.81 billion against an estimated $2.50 billion. Despite a decline in Covid vaccine sales, Moderna's stock rose as it gained market share from Pfizer. Additionally, Moderna outlined a commercial roadmap for its experimental respiratory syncytial virus (RSV) vaccine, signaling a strategic move beyond Covid vaccines after a challenging year of transition.